AlgoTx Announces Results of its Phase 2 “ACT” Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
Paris, France, 18 February 2025: AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral neuropathic pain, ATX01, announced today the completion of its 276 patient Phase 2 trial known as ‘ACT’ (ATX01 in ChemoTherapy-induced peripheral neuropathy).
